Acorda Therapeutics Inc $31.01

down -1.05


9/7/2014 04:00 PM  |  NASDAQ : ACOR  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ACOR Trend Analysis - it has underperformed the S&P 500 by 33%

Partner Headlines

  1. Markets Edge Higher; Alcoa Profit Beats Street View

    Benzinga
  2. Benzinga's Volume Movers

    Benzinga
  3. Market Wrap For June 17: Markets Higher Ahead Of Fed Decision

    Benzinga
  4. Mid-Afternoon Market Update: Oil Falls, US Indexes Rise In Afternoon Session

    Benzinga
  5. Mid-Day Market Update: Amira Rises On Upbeat Earnings; Acorda Therapeutics ...

    Benzinga
  6. Mid-Morning Market Update: Markets Gain; FactSet Posts Rise In Revenue

    Benzinga
  7. Morning Market Losers

    Benzinga
  8. Citigroup downgraded Acorda Therapeutics, Says Fundamentals Have Reversed ...

    Benzinga
  9. Acorda Therapeutics Announces European Patent Office Upholds Fampridine ...

    Benzinga
  10. Acorda Presents New Diazepam Nasal Spray Data at 67th Annual Meeting of ...

    Benzinga
  11. Acorda Therapeutics Reports Data from Phase 2 Trial of Delfampridine-ER, ...

    Benzinga
  12. Acorda Therapeutics Could Be a Stock to Watch in 2013

    Benzinga
  13. UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, ...

    Benzinga
  14. A Peek Into The Market Before The Trading Starts

    Benzinga
  15. Acorda Therapeutics, Inc. (ACOR) CFO David Lawrence sells 9,313 Shares

    GuruFocus
  16. Acorda Therapeutics, Inc. (ACOR) President and CEO Ron Cohen sells 16,4 ...

    GuruFocus
  17. Acorda Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus
  18. Acorda Therapeutics Names Jane Wasman President, International

    Benzinga
  19. UPDATE: Aegis Capital Corp Initiates Buy on Acorda Therapeutics on Ampyra ...

    Benzinga
  20. Tesoro, Focus Media Among Stocks Up on High Volume Monday

    FoxBusiness
  21. Benzinga's Top Pre-Market Gainers

    Benzinga
  22. Acorda Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus
  23. Health Care Sector Wrap

    FoxBusiness
  24. From Earlier: Acorda Therapeutics Announces Initiation of AMPYRA® Proof-of-Concept ...

    Benzinga
  25. A Peek Into The Market Before The Trading Starts

    Benzinga
  26. Acorda Therapeutics Announces Initiation of AMPYRA® Proof-of-Concept Study ...

    Benzinga
  27. UPDATE: Goldman Sachs Initiates Sell on Acorda Therapeutics; Ampyra Risk

    Benzinga
  28. Acorda Therapeutics Inc. Reports Operating Results (10-K)

    GuruFocus
  29. Acorda Therapeutics Announces Launch of Authorized Generic Version of ZANAFLEX ...

    Benzinga
  30. 5 Speculative Biotech Stocks to Consider Buying Now

    GuruFocus
  31. JP Morgan Downgrades ACOR, ALTH, AMGN, VPHM

    Benzinga
Trading Center